Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32978
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuddart, R-
dc.contributor.authorHafeez, S-
dc.contributor.authorOmar, A-
dc.contributor.authorAlonzi, R-
dc.contributor.authorBirtle, A-
dc.contributor.authorCheung, K C-
dc.contributor.authorChoudhury, A-
dc.contributor.authorForoudi, Farshad-
dc.contributor.authorGribble, H-
dc.contributor.authorHenry, A-
dc.contributor.authorHilman, S-
dc.contributor.authorHindson, B-
dc.contributor.authorLewis, R-
dc.contributor.authorMuthukumar, D-
dc.contributor.authorMcLaren, D B-
dc.contributor.authorMcNair, H-
dc.contributor.authorNikapota, A-
dc.contributor.authorOlorunfemi, A-
dc.contributor.authorParikh, O-
dc.contributor.authorPhilipps, L-
dc.contributor.authorRimmer, Y-
dc.contributor.authorSyndikus, I-
dc.contributor.authorTolentino, A-
dc.contributor.authorVarughese, M-
dc.contributor.authorVassallo-Bonner, C-
dc.contributor.authorWebster, A-
dc.contributor.authorGriffin, C-
dc.contributor.authorHall, E-
dc.date2023-
dc.date.accessioned2023-06-07T02:37:18Z-
dc.date.available2023-06-07T02:37:18Z-
dc.date.issued2023-09-
dc.identifier.citationClinical Oncology (Royal College of Radiologists (Great Britain)) 20232023-09; 35(9)en_US
dc.identifier.issn1433-2981-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32978-
dc.description.abstractAdding concurrent (chemo)therapy to radiotherapy improves outcomes for muscle-invasive bladder cancer patients. A recent meta-analysis showed superior invasive locoregional disease control for a hypofractionated 55 Gy in 20 fractions schedule compared with 64 Gy in 32 fractions. In the RAIDER clinical trial, patients undergoing 20 or 32 fractions of radical radiotherapy were randomised (1:1:2) to standard radiotherapy or to standard-dose or escalated-dose adaptive radiotherapy. Neoadjuvant chemotherapy and concomitant therapy were permitted. We report exploratory analyses of acute toxicity by concomitant therapy-fractionation schedule combination. Participants had unifocal bladder urothelial carcinoma staged T2-T4a N0 M0. Acute toxicity was assessed (Common Terminology Criteria for Adverse Events) weekly during radiotherapy and at 10 weeks after the start of treatment. Within each fractionation cohort, non-randomised comparisons of the proportion of patients reporting treatment emergent grade 2 or worse genitourinary, gastrointestinal or other adverse events at any point in the acute period were carried out using Fisher's exact tests. Between September 2015 and April 2020, 345 (163 receiving 20 fractions; 182 receiving 32 fractions) patients were recruited from 46 centres. The median age was 73 years; 49% received neoadjuvant chemotherapy; 71% received concomitant therapy, with 5-fluorouracil/mitomycin C most commonly used: 44/114 (39%) receiving 20 fractions; 94/130 (72%) receiving 32 fractions. The acute grade 2+ gastrointestinal toxicity rate was higher in those receiving concomitant therapy compared with radiotherapy alone in the 20-fraction cohort [54/111 (49%) versus 7/49 (14%), P < 0.001] but not in the 32-fraction cohort (P = 0.355). Grade 2+ gastrointestinal toxicity was highest for gemcitabine, with evidence of significant differences across therapies in the 32-fraction cohort (P = 0.006), with a similar pattern but no significant differences in the 20-fraction cohort (P = 0.099). There was no evidence of differences in grade 2+ genitourinary toxicity between concomitant therapies in either the 20- or 32-fraction cohorts. Grade 2+ acute adverse events are common. The toxicity profile varied by type of concomitant therapy; the gastrointestinal toxicity rate seemed to be higher in patients receiving gemcitabine.en_US
dc.language.isoeng-
dc.subjectAcute toxicityen_US
dc.subjectbladderen_US
dc.subjectchemotherapyen_US
dc.subjectradiotherapyen_US
dc.titleAcute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical Oncology (Royal College of Radiologists (Great Britain))en_US
dc.identifier.affiliationDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UKen_US
dc.identifier.affiliationRadiotherapy Department, The Royal Marsden NHS Foundation Trust, London, UK.en_US
dc.identifier.affiliationClinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK.en_US
dc.identifier.affiliationClinical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK.en_US
dc.identifier.affiliationCancer Oncology, Lancashire Teaching Hospitals NHS Trust, Lancashire, UK.en_US
dc.identifier.affiliationTranslational Radiobiology, The Christie NHS Foundation Trust, Manchester, UK.en_US
dc.identifier.affiliationRadiation Oncologyen_US
dc.identifier.affiliationUniversity of Leeds and the Leeds Teaching Hospital NHS Trust, Leeds, UK.en_US
dc.identifier.affiliationClinical Oncology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.en_US
dc.identifier.affiliationCanterbury Regional Cancer and Haematology Service, Te Whatu Ora, Waitaha Canterbury, Christchurch, New Zealand.en_US
dc.identifier.affiliationOncology, East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.en_US
dc.identifier.affiliationDepartment of Clinical Oncology, Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK.en_US
dc.identifier.affiliationClinical Oncology, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.en_US
dc.identifier.affiliationLancashire Teaching Hospitals NHS Trust, Burnley, UK.en_US
dc.identifier.affiliationDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.en_US
dc.identifier.affiliationDepartment of Radiotherapy, The Clatterbridge Cancer Centre, Liverpool, UK.en_US
dc.identifier.affiliationDepartment of Oncology, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.en_US
dc.identifier.affiliationPatient Representative, The Institute of Cancer Research, London, UK.en_US
dc.identifier.affiliationNational Radiotherapy Trials Quality Assurance Group (RTTQA), University College Hospital, London, UK.en_US
dc.identifier.doi10.1016/j.clon.2023.05.002en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37225552-
local.name.researcherForoudi, Farshad-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Jun 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.